New drug combo aims to shrink Hard-to-Treat tumors
NCT ID NCT06400160
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-stage trial tests a new drug called TB511, alone or with pembrolizumab, in 12 adults with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that stopped responding to standard treatments. The goal is to find the safest dose and see if it can shrink tumors. This is not a cure; it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.